https://orcid.org/0000-0002-1621-6477
References
- Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111(3):1366–1377.
- García-Muñoz R, Galar A, Moreno C, et al. Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma. 2007;48(12):2461–2464.
- Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398–1405.
- Ishiyama K, Kitawaki T, Sugimoto N, et al. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph + leukemia patients treated with dasatinib. Leukemia. 2017;31(1):203–212.
- Kadowaki N, Ishiyama K, Kitawaki T. Cytomegalovirus pulls strings behind NK cells. Oncotarget. 2017;8(55):93297–93298.
- Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
- Yim E, Choi YG, Nam YJ, et al. Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia. Korean J Intern Med. 2018;33(2):446–448.
- Choi JK, Cho SY, Choi SM, et al. Cytomegalovirus colitis during dasatinib treatment for patients with hematologic malignancy: case series and literature review. Infect Chemother. 2018;50(2):153–159.
- Oshima N, Mishima Y, Shibagaki K, et al. Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report. BMC Gastroenterol. 2021;21(1):19.
- Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
- Climent N, Plana M. Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral Infection. Front Pharmacol. 2019;10:1232.
- Nishiwaki S, Maeda M, Yamada M, et al. Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients. Blood. 2017;129(1):126–128.
- Aldoss I, Gaal K, Al Malki MM, et al. Dasatinib-induced colitis after allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2016;22(10):1900–1903.
- Yang H, Zhou W, Lv H, et al. The association between CMV viremia or endoscopic features and histopathological characteristics of CMV colitis in patients with underlying ulcerative colitis. Inflammatory Bowel Dis. 2017;23(5):814–821.
- Iwasaki T. Alimentary tract lesions in cytomegalovirus infection. Acta Pathol Jpn. 1987;37(4):549–565.
- Le PH, Kuo CJ, Wu RC, et al. Pancolitis associated with higher mortality risk of cytomegalovirus colitis in patients without inflammatory bowel disease. Ther Clin Risk Manag. 2018;14:1445–1451.
- Tamilarasan AG, Katelaris P, Gasiorowski R, et al. Dasatinib-induced colitis: a case report. Pathology. 2019;51(7):757–759.
- Chisti MM, Khachani A, Brahmanday GR, et al. Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis. BMJ Case Reports. 2013;2013(dec12 1):bcr2013200610–bcr2013200610.
- Yassin MA, Nashwan AJ, Soliman AT, et al. Cytomegalovirus-induced hemorrhagic colitis in a patient with chronic myeloid leukemia (chronic phase) on dasatinib as an upfront therapy. Clinical Medicine Insights Case Reports. 2015;8:77–81.